tyrosine kinase


Also found in: Dictionary, Thesaurus, Encyclopedia, Wikipedia.
Related to tyrosine kinase: Tyrosine Kinase Receptor

ty·ro·sine ki·nase

an enzyme that phosphorylates tyrosyl residues on certain proteins; many are products of viral oncogenes; a number of receptors (for example, receptors for epidermal growth factor, insulin, etc.) have this enzymatic activity; a misnomer, in that the physiologic substrate is not tyrosine but tyrosyl residues in a protein.

tyrosine kinase

n.
Any of a family of enzymes that phosphorylate tyrosine in certain proteins and play an important role in cell signaling. Mutations that affect their activity or expression can cause leukemia and other cancers.

tyrosine kinase

An enzyme intimately linked to signal transduction–ST, either as a receptor-type TK, which participates in transmembrane signaling, or as an intracellular TK, participating in ST to the nucleus; ↑ or ↓ TK activity is associated with various diseases, and alteration of TK activity at various points in its signaling pathway is of potential therapeutic interest; ↑ TK activity implicated in many CAs and other malignant and nonmalignant diseases, ASHD, psoriasis, inflammation; ↓ TK activity is linked to DM, X-linked agammaglobulinemia

tyrosine kinase

Any of a group of enzymes that influence signaling between cells, esp. as relates to cell growth and death, cellular adhesion and movement, and cellular differentiation. Abnormalities in tyrosine kinases are found in some human diseases, including chronic myeloid (myelogenous) leukemia.
See also: kinase
References in periodicals archive ?
Introduction & Categorization of Cancer Targeted Therapies - Mechanism of Cancer Targeted Tyrosine Kinase, Vaccines, Oncogenes Inhibitors, Monoclonal Antibodies - Cancer Targeted Therapy Clinical Pipeline by Company, Indication & Phase - Clinical Insight on More Than 1200 Cancer Targeted Therapies in Pipeline - Clinical Insight & Patent Analysis of Marketed Cancer Targeted Therapies - Global Cancer Targeted Therapeutics Market Dynamics - Future Prospects of Cancer Targeted Therapies
These data suggest a way in which receptor tyrosine kinase inhibitors could be used to treat individuals with KRAS mutant colorectal cancers.
The tyrosine kinases are often dysregulated in malignancy.
Overview of second-generation tyrosine kinase inhibitors for patients with imatinib-resistant chronic myelogenous leukemia.
The development of tyrosine kinase inhibitors in gastrointestinal malignancy
10 ng/mL) and soluble fms-like tyrosine kinase 1 (sFlt1) levels were nearly threefold higher (6,356 vs.
Specifically, Tarceva inhibits tyrosine kinase activity, which is associated with EGFR.
Overexpression of ERK, an EPH family receptor protein tyrosine kinase, in various human tumors.
Exposure to R5 gp120 and X4 gp 120 resulted in activation of pro line-rich tyrosine kinase 2 (Pyk2), a non-receptor tyrosine kinase related to focal adhesion kinase.
Mutation of unique region of Bruton's tyrosine kinase in immunodeficient XID mice.
Reports from The Netherlands indicate that as certain breast cells become increasingly malignant, the activity of tyrosine kinase increases.
The first study, "Ponatinib, a potent pan-BCR-ABL inhibitor, retains activity against gatekeeper mutants of FLT3, RET, KIT, PDGFR and FGFR1," was presented yesterday and shows that ponatinib overcomes resistant gatekeeper mutations well beyond BCR-ABL -- the drug's target in chronic myeloid leukemia (CML) and Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL) -- in other clinically relevant tyrosine kinase targets.

Full browser ?